Document is current
Any future updates will be listed below
-
Authors
Khazamipour, Nastaran
Oo, Htoo Zarni https://orcid.org/0009-0009-8514-2713
Al-Nakouzi, Nader
Marzban, Mona
Khazamipour, Nasrin
Roberts, Morgan E https://orcid.org/0000-0002-5850-7985
Farivar, Negin
Moskalev, Igor
Lo, Joey
Ghaidi, Fariba
Nelepcu, Irina https://orcid.org/0000-0002-9208-6934
Moeen, Alireza
Truong, Sarah https://orcid.org/0000-0003-0950-6684
Dagil, Robert https://orcid.org/0000-0002-5594-0716
Choudhary, Swati
Gustavsson, Tobias
Zhai, Beibei https://orcid.org/0009-0001-6303-6313
Heitzender, Sabine
Salanti, Ali https://orcid.org/0000-0003-2207-5575
Sorensen, Poul H https://orcid.org/0000-0001-7447-2199
Daugaard, Mads https://orcid.org/0000-0001-8383-055X
-
Funding
Funding for this research was provided by:
St. Baldrick's Foundation/ American Association for Cancer Research/ Stand Up to Cancer Pediatric Dream Team Translational Research Grant (SU2C-AACR-DT-27-17)
NIH Prostate Cancer PNW-SPORE (1016339,223493; 5P50 CA097186-17)
Canadian Government | CIHR | Canadian Institutes of Health Research - Antimicrobial Resistance Research Initiative (PJT-153092)
University of British Columbia (UBC), UBC Four year Fellowships (#6456)
Canadian Urological Association Scholarship Fund
CIHR travel Award- Michael Smith Foreign Study Supplement (6580)
NNF Tandem grant (NNF21OC0068192)
NNF Distinguished Innovator grant (NNF22OC0076055)
CIHR-Vanier scholarship (01353-000)
- License Information
-
More Information
Article History
Received: 31 May 2024
Revised: 24 September 2024
Accepted: 1 October 2024
First Online: 15 October 2024
Disclosure and competing interests statement
: MD as the corresponding author certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: MD, AS, and PHS are co-founders of, and shareholders in, VAR2 Pharmaceuticals. NAN and TG are consultants for VAR2 Pharmaceuticals. VAR2 Pharmaceuticals is a biotechnology company that specializes in the therapeutic development of the VAR2CSA technology ( ). The remaining authors declare no competing interests.
